Neoplasms
1,105
129
176
631
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
217 trials with published results (20%)
Research Maturity
631 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.9%
132 terminated out of 1105 trials
82.7%
-3.8% vs benchmark
6%
69 trials in Phase 3/4
34%
217 of 631 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 631 completed trials
Clinical Trials (1105)
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Effects of a Lay-led Anxiety and Depression Self-management Program for Cancer Patients
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
100-Year Human Aging Study
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
A Study of JNJ-1761981 in Participants With Solid Tumors
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
A Study of JNJ-87890387 for Advanced Solid Tumors
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring